Pharmacogenetics in Europe: Barriers and Opportunities

D. Gurwitz, E. Zika, M.M. Hopkins, S. Gaisser, D. Ibarreta
2009 Public Health Genomics  
sector to invest in the development and licensing of PGx diagnostic tests for improving the safety and efficacy of outof-patent drugs. It therefore seems that one key aspect where policy can affect the clinical uptake of PGx is via sustaining large-scale industry-academia collaborations for developing and proving the utility of PGx diagnostics.
doi:10.1159/000189625 pmid:19204415 fatcat:s2v36h2sqzgg5jz47txsowtzae